Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/6540


The National Institute of Clinical Excellence in CNS: A Major Impact on the European Market


Description: The National Institute of Clinical Excellence (Nice) is a regulatory body set up by the UK government in 1999. Nice is responsible for providing guidance on the usage of new technologies and how specific diseases should be treatment managed. Its clinical guidance can dramatically alter the dynamics of a particular market, with a positive approval from Nice likely to result in a significant increase in the revenues that particular compound will get from the UK and the European market.Detailed analysis of the establishment of Nice, its aims, authority and methodologiesIn-depth profiles of the guidance published for Cox-ii inhibitors, Alzheimer’s disease, multiple sclerosis, smoking cessation and schizophreniaDatamonitor strategic recommendations regarding how competing pharmaceutical manufacturers should react to these decisionsAn analysis of what impact Nice has had on different aspects of the healthcare system, such as budgetary considerations and physician independenceA focus upon the impact of Nice in markets outside the UK and what areas in CNS the Institute will be providing guidance upon in the near futureNice guidance has also resulted in changes to the wider healthcare system which pharmaceutical companies can take advantage of to increase revenues.The impact of Nice is being increasingly felt across Europe, meaning that its decisions now affect the commercial performance of drugs in markets outside the UK market.Understand the key dynamics behind Nice and what is its remitEnhance your knowledge about the influence of Nice on various aspects of the UK and European healthcare marketDiscover what different impacts Nice has had in specific CNS marketsEvaluate the clear need to develop multiple strategies to deal with pending Nice decisions


Contents: Overview

Introduction


The National Institute of Clinical Excellence (NICE) is a regulatory body set up by the UK government in 1999. NICE is responsible for providing guidance on the usage of new technologies and how specific diseases should be treatment managed. Its clinical guidance can dramatically alter the dynamics of a particular market, with a positive approval from NICE likely to result in a significant increase in the revenues that particular compound will get from the UK and the European market.


Scope



  • Detailed analysis of the establishment of NICE, its aims, authority and methodologies


  • In-depth profiles of the guidance published for COX-II inhibitors, Alzheimer’s disease, multiple sclerosis, smoking cessation and schizophrenia


  • Datamonitor strategic recommendations regarding how competing pharmaceutical manufacturers should react to these decisions


  • An analysis of what impact NICE has had on different aspects of the healthcare system, such as budgetary considerations and physician independence


  • A focus upon the impact of NICE in markets outside the UK and what areas in CNS the Institute will be providing guidance upon in the near future



Report Highlights


NICE guidance has also resulted in changes to the wider healthcare system which pharmaceutical companies can take advantage of to increase revenues.


The impact of NICE is being increasingly felt across Europe, meaning that its decisions now have an effect on the commercial performance of drugs in markets outside the UK market.


Reasons to Purchase



  • Understand the key dynamics behind NICE and what is its remit


  • Enhance your knowledge about the influence of NICE on various aspects of the UK and European healthcare market


  • Discover what different impacts NICE has had in specific CNS markets


  • Evaluate the clear need to develop multiple strategies to deal with pending NICE decisions



DRIVERS AND TRENDS


This Market Brief will help answer strategic planning questions such as:


What CNS markets have NICE already provided guidance on?


How has this impacted competing pharmaceutical manufacturers?


What has been the impact of NICE in other areas of the healthcare system?


What is the impact of NICE in other key pharmaceutical markets?


What is the future for NICE?


Which other CNS markets are going to be reviewed in the near future?


INTRODUCTION


An overview of the what NICE is, why it was established, its aims, methodologies and which CNS markets it has already produced guidance on


KEY RECENT NICE CNS INITATIVES


In-depth analysis of published NICE guidelines, what they actually mean and Datamonitor recommended strategies about how pharmaceutical manufacturers should react in the follow disorders:


Cox-II inhibitors in arthritic disorders


Alzheimer’s disease


Multiple sclerosis


Smoking cessation


Schizophrenia


NICE: ITS IMPACT AND FUTURE DEVELOPMENT


A comprehensive analysis of the impact of NICE on other areas of the healthcare system such as physician independence and National Health System budgets


An outline of the impact of NICE in markets outside the UK


A focus on the future development of NICE and the areas within CNS it is currently preparing guidance for


ACTION POINTS


Key action points for pharmaceutical companies:


Action point 1 – The rulings of NICE on various CNS markets have produced both positive and negative commercial opportunities for pharmaceutical manufacturers.


Action point 2 – NICE guidance has also resulted in changes to the wider healthcare system which pharmaceutical companies can take advantage of to increase revenues.


Action point 3 – The re-election of the Labour government in the UK means that the authority of NICE is likely to be strengthened over the next five years.


Action point 4 – The impact of NICE is being increasingly felt across the EU, meaning that its decisions now have an affect upon the commercial performance of drugs in markets outside the UK market.


DATASETS


Table 1: NICE guidelines on COX-II inhibitors: key facts


Table 2: NICE guidelines on Alzheimer’s disease: key facts


Table 3: NICE guidelines on multiple sclerosis: key facts


Table 4: NICE guidelines on smoking cessation: key facts


Table 5: NICE guidelines on the use of atypical neuroleptics for treating schizophrenia: key facts


Figure 1: Examples of Datamonitor recommendations following NICE guidance in a number of CNS Markets





Ordering: Order Online - visit http://www.researchandmarkets.com/reports/6540

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 13/10/2008 08:38:07
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
The National Institute of Clinical Excellence in CNS: A Major Impact on the European Market
Web Address:
http://www.researchandmarkets.com/reports/6540
Office Code:
OCHKFPRNRPT

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €1,669.00 + EUR€ 50.00 Shipping/Handling *
Electronic €2,033.00
Electronic - Site License €1,605.00

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 13/10/2008 08:38:07

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World